Spinal cord injury (SCI) results from traumatic (motor vehicle accident, fall, violence) or non-traumatic causes (tumour, infection, vascular malformation). Severity ranges from incomplete (some motor or sensory function preserved) to complete paraplegia or tetraplegia (total loss of function). Rehabilitation focuses on maximising functional independence, preventing complications, and optimising quality of life within motor limitations.
Acute management stabilises the spine, prevents secondary injury, and commences neuroprotective therapy. High-dose methylprednisolone is used within 8 hours in some centres, though benefit is modest. Acute rehabilitation includes immobilisation, prevention of pressure ulcers through turning protocols and air-loss mattresses, and catheterisation for neurogenic bladder. Chronic rehabilitation combines physiotherapy (strengthening of preserved motor function, range-of-motion maintenance, transfer training) and occupational therapy (adaptive equipment, wheelchair prescription, home modification). Pharmacological management addresses spasticity (baclofen, tizanidine, botulinum toxin), neuropathic pain (gabapentin, pregabalin, duloxetine), and neurogenic bladder/bowel. Cardiovascular fitness and psychological support are essential. Assistive devices (wheelchairs, orthoses, electrical stimulation) promote mobility and independence.
Acupuncture is explored for pain and spasticity management with variable outcomes reported; robust evidence is limited. Traditional Chinese medicine approaches are practised. Herbal remedies and nutritional supplementation focusing on neuroprotection (antioxidants, omega-3 fatty acids, magnesium) are explored, though clinical validation is lacking. Hyperbaric oxygen therapy is investigated in some centres for potential neuroprotection, despite inconsistent evidence. Psychological interventions including mindfulness and adaptive coping strategies support emotional wellbeing.
Stem cell therapy is studied for SCI, with bone marrow-derived stem cells, neural stem cells, and olfactory ensheathing cells investigated in multiple clinical trials. Proposed mechanisms include neuroprotection, reduction of inflammation, promotion of axonal growth and remyelination, and restoration of neuronal circuits. Several Phase 1 and Phase 2 trials have reported improvements in motor and sensory function when administered within months of injury; outcomes vary substantially, and efficacy is not yet established. Clinical protocols remain experimental, and candidacy is restricted to acute to subacute SCI (typically <2 years). Candidate assessment requires MRI confirmation of spinal cord preservation and absence of systemic contraindications.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Acute spinal stabilisation & imaging | Standard | Strong | €3,000–€8,000 | High | 4–8 weeks |
| Inpatient rehabilitation (spasticity, ADL training) | Standard | Strong | €200–€400/day | Low | Ongoing |
| Wheelchair prescription & assistive devices | Standard | Strong | €2,000–€15,000 | Low | Immediate |
| Spasticity management (pharmacotherapy, botulinum toxin) | Standard | Strong | €100–€1,500 per injection | Low | 1–2 weeks |
| Herbal & antioxidant supplementation | Alternative | Limited | €40–€100/month | Low | Ongoing |
| Acupuncture for pain & spasticity | Alternative | Limited | €70–€140 per session | Low | Immediate |
| Neural stem cell transplantation | Regenerative | Investigational | €30,000–€60,000 | High | 6–12 weeks |
| Functional electrical stimulation (FES) | Standard | Moderate | €5,000–€20,000 | Medium | 4–8 weeks |
Complete SCI historically carries poor prognosis for neurological recovery. Emerging therapies including stem cell transplantation and neuroregenerative approaches are investigational; spontaneous recovery occasionally occurs. Focus remains on maximising functional independence within motor limitations and preventing complications.
Management includes intermittent catheterisation, medications (anticholinergics, beta-3 agonists), electrical stimulation, and surgical intervention (augmentation cystoplasty, continent stoma) in selected cases. Individuised protocols optimise continence and renal health.
FES uses electrical stimulation of paralysed muscles to produce movement and improve strength. In incomplete SCI, FES may enhance walking capacity; in complete SCI, it typically augments therapy without restoring independent ambulation. Benefit varies individually.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită